Evidence map›Paper›PMID 41027430›Full record

ArticleCell reports. Medicine2025

Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density.

Alex Quan, Mingyu Huo, Dan Li, Laura E Hutchins, Constanza Rodriguez, Jangsuk Oh, Hsi-En Tsao, Madeline Spetz, Elijah Edmondson, Dana Ashworth and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Alex QuanLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Mingyu HuoLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Dan LiLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Laura E HutchinsLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Constanza RodriguezPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Jangsuk OhPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Hsi-En TsaoLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Madeline SpetzLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Elijah EdmondsonMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Dana AshworthSpatomics LLC, 246 Goose Ln, Ste 202A, Guilford, CT 06437, USA.
Rui ZhengSpatomics LLC, 246 Goose Ln, Ste 202A, Guilford, CT 06437, USA.
Jing ZhouSpatomics LLC, 246 Goose Ln, Ste 202A, Guilford, CT 06437, USA.
Jinyun ChenEureka Therapeutics Inc., 5858 Horton Street, Suite 370, Emeryville, CA 94608, USA.
Jingbao LiuEureka Therapeutics Inc., 5858 Horton Street, Suite 370, Emeryville, CA 94608, USA.
Guangyan XiongEureka Therapeutics Inc., 5858 Horton Street, Suite 370, Emeryville, CA 94608, USA.
Hongbing ZhangEureka Therapeutics Inc., 5858 Horton Street, Suite 370, Emeryville, CA 94608, USA.
Cheng LiuEureka Therapeutics Inc., 5858 Horton Street, Suite 370, Emeryville, CA 94608, USA.
Rosa NguyenPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Nan LiLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Mitchell HoLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. Electronic address: homi@mail.nih.gov.

Funding

Development of new antibody-based cancer therapiesZIABC010891 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HO, MITCHELL · 2009 to 2025
$21.4M
Antibody Therapy of CancerZ01BC010891 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HO, MITCHELL · 2008 to 2008
$56k
Intramural NIH HHS Z01 BC010891Intramural NIH HHS ZIA BC010891
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cells have shown promise in hematological cancers but face challenges in solid tumors, partly due to heterogeneous antigen density. Glypican-2 (GPC2) is an oncofetal antigen highly expressed in neuroblastoma and under evaluation in phase 1 clinical trials. Here, we engineer T cells with antibody-T cell receptors (AbTCRs) targeting GPC2. We generate autologous AbTCR T cells using CT3 or humanized CT3 (hCT3) antigen-binding fragments (Fab) linked to γ/δ T cell receptors (TCRs), along with a CD30 co-stimulatory domain. Both CT3 and hCT3 AbTCR T cells show superior antitumor efficacy compared to CT3 CAR T cells, with hCT3 AbTCR T cells inducing significant regression in neuroblastoma with low GPC2 antigen density. Enhanced efficacy is associated with stronger TCR signaling, expansion of stem cell-like memory T cells, and improved CD8

Indexed as

GlypicansNeuroblastomaReceptors, Antigen, T-Cell, gamma-deltaAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunotherapy, AdoptiveMiceReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesGlypicansReceptors, Antigen, T-CellReceptors, Antigen, T-Cell, gamma-deltaReceptors, Chimeric AntigenAbTCRantibody humanizationantibody-TCRCARCD30cell therapychimeric antigen receptorgamma/delta TCRglypican-2GPC2monoclonal antibodyneuroblastoma

Identifiers

PMID41027430
PMCPMC12629815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.